Keywords
How to Cite
Abstract
Complejo Protrombínico UNC (CP-UNC) is a plasma derived concentrate containing coagulation factors II, IX and X. It is prepared in Argentina and has the approval of the National Administration of Drugs, Foods and Medical Devices (ANMAT). In the present case report we described the use of CPUNC for reversal of hypoprothrombinemia prior to liver transplantation (two patients) and vitamin K antagonists (two patients). CP-UNC was used in different doses according weight, patient's clinical situation and laboratory data. The parameters of effectiveness, adverse drug reactions (ADR) and viral markers (MV) were evaluated in each case. The results showed that the CP-UNC improved the laboratory parameters within the expected values. An acute coronary syndrome was reported in one patient. It was categorized as possible using the Naranjo algorithm. There were no hemorrhagic complications in the other patients. Until now, no RAM reports have been received under the Pharmacovigilance Program implemented for this concentrate.
References
2. Naranjo C, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al. A method for estimating the probability of adverse drug reactions. Clin Pharm Ther. 1981; 30:239-45.
3. Sevilla B, Roldan I, Baello P et al. Síndrome antifosfolípido con infarto de miocardio y afectación valvular
aórtica. Rev Esp Cardiol. 2000; Vol 53:1534-36.
4. Menache, D. Report of the Task-Force on the clinical use of FIX concentrates. International Committee
Communication. Thrombosis and Haemostasis. 1976; 35, 748-750.
5. Bernardi ME, Vitali MS, Moya C, Guglielmone HA, Cuadra GR. Studies in animal model on the thrombogenicity of a new prothrombin complex concentrate from Argentina. Transf Med. 2007; 17:420-422.
6. Barillari G, Pasca S, Barillari A, De Angelis V. Emergency reversal of anticoagulation: from theory to real use
of prothrombin complex concentrates. A retrospective Italian experience. Blood Transfus. 2012; 10(1):87-94.
7. Levi M, Moore K, Castillejos C et al. Comparison of three factor and four factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost. 2014; 12(9):1428-36.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar